Table 1 Baseline characteristics of participants in the discovery and validation cohorts
From: DNA methylation predicts adverse outcomes of coronary artery disease
Characteristics | Discovery cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
Survival (N = 188) | Death (N = 217) | P-value | Survival (N = 503) | Death (N = 25) | P-value | |
Demographic data | ||||||
Age (year) | 62.7 ± 9.4 | 70.02 ± 9.82 | 1.67E-13 | 61.89 ± 9.52 | 69.36 ± 9.89 | 3.10E-04 |
Male | 133 (70.74) | 165 (76.04) | 2.75E-01 | 369 (73.36) | 19 (76) | 9.52E-01 |
Medical history | ||||||
Diabetes mellitus | 58 (30.85) | 82 (37.79) | 1.74E-01 | 145 (28.83) | 7 (28) | 7.20E-01 |
Hypertension | 100 (53.19) | 146 (67.28) | 5.21E-03 | 287 (57.06) | 18 (72) | 1.17E-01 |
Heart failure | 61 (32.45) | 132 (60.83) | 2.10E-08 | 229 (45.53) | 13 (52) | 3.88E-01 |
Arrhythmia | 10 (5.32) | 30 (13.82) | 7.05E-03 | 44 (8.75) | 4 (16) | 1.01E-01 |
Current smoking | 59 (31.38) | 80 (36.87) | 2.92E-01 | 144 (28.63) | 7 (28) | 1.00E + 00 |
Biomedical measurements* | ||||||
ALT, U/L | 26.75 ± 14.06 | 39.53 ± 75.78 | 2.46E-02 | 27.27 ± 14.72 | 23.4 ± 77.6 | 4.44E-01 |
AST, U/L | 26.47 ± 12.66 | 45.96 ± 83.88 | 1.83E-03 | 27.62 ± 12.9 | 67.42 ± 85.75 | 6.36E-05 |
LDLC, mmol/L | 2.74 ± 0.94 | 2.55 ± 0.97 | 4.60E-02 | 2.71 ± 0.94 | 2.77 ± 0.96 | 7.89E-01 |
HDLC, mmol/L | 1 ± 0.26 | 0.95 ± 0.27 | 6.58E-02 | 1.01 ± 0.27 | 1.02 ± 0.26 | 9.13E-01 |
Triglyceride, mmol/L | 1.65 ± 1.36 | 1.5 ± 1.03 | 2.10E-01 | 1.86 ± 1.33 | 1.48 ± 1.05 | 3.82E-01 |
ApoA, g/L | 1.09 ± 0.26 | 1.01 ± 0.29 | 5.24E-03 | 1.16 ± 0.29 | 1.16 ± 0.26 | 9.22E-01 |
TC, mmol/L | 4.43 ± 1.15 | 4.24 ± 1.18 | 1.06E-01 | 4.31 ± 1.14 | 4.34 ± 1.18 | 9.44E-01 |
LPA, mg/dL | 235.67 ± 227.07 | 366.56 ± 379.82 | 2.38E-04 | 290.1 ± 232.1 | 248.94 ± 382.65 | 5.96E-01 |
CK, U/L | 117.13 ± 154.52 | 197.08 ± 571.22 | 7.22E-02 | 132.03 ± 150.49 | 534.46 ± 584.71 | 7.52E-05 |
CKMB, U/L | 7.57 ± 6.65 | 12.19 ± 29.3 | 4.12E-02 | 18.64 ± 6.51 | 10.25 ± 29.98 | 4.70E-01 |
Creatinine, μmol/L | 83.92 ± 26.79 | 142.36 ± 153.39 | 3.98E-07 | 91.91 ± 25.21 | 142.42 ± 156.78 | 5.78E-04 |
Glucose, mmol/L | 6.64 ± 2.86 | 7.12 ± 3.45 | 1.36E-01 | 6.08 ± 2.79 | 6.33 ± 3.52 | 6.34E-01 |
Medication** | ||||||
Aspirin | 183 (97.34) | 200 (92.17) | 4.04E-02 | 444 (88.27) | 16 (64) | 6.17E-03 |
Clopidogrel | 177 (94.15) | 208 (95.85) | 5.62E-01 | 409 (81.31) | 16 (64) | 1.64E-01 |
PPI | 94 (50) | 126 (58.06) | 1.08E-01 | 322 (64.02) | 14 (56) | 7.96E-01 |
ACEI | 83 (44.15) | 117 (53.92) | 5.12E-02 | 250 (49.7) | 9 (36) | 5.14E-01 |
BB | 166 (88.3) | 180 (82.95) | 1.79E-01 | 408 (81.11) | 17 (68) | 2.74E-01 |
CCB | 68 (36.17) | 99 (45.62) | 5.36E-02 | 146 (29.03) | 8 (32) | 4.73E-01 |
Surgical history | ||||||
PCI | 125 (66.49) | 160 (73.73) | 0.138 | 345 (68.59) | 13 (52) | 3.62E-01 |
